Home
HelpTest Code ERPR Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual
Reporting Name
ER/PR Semi Quant IHC ManualUseful For
Guiding decisions on hormonal therapy in patients with breast carcinomas
This test is not useful for cases of lobular carcinoma in situ.
Method Name
Semi-Quantitative Immunohistochemistry
Performing Laboratory
Mayo Clinic Laboratories in Rochester
Specimen Type
SpecialOrdering Guidance
This test is for prognostic purposes only.
For diagnostic purposes, order PATHC / Pathology Consultation and then request the stains.
Estrogen/progesterone receptor testing is not appropriate and not performed for cases of lobular carcinoma in situ.
Shipping Instructions
Attach the green pathology address label included in the kit to the outside of the transport container.
Necessary Information
1. Include accompanying pathology report stating the final diagnosis. If not available, a preliminary diagnosis is acceptable.
2. Information regarding fixative used, time to fixation, and duration of fixation is required. The following questions, as stated on the order form or presented electronically, must be answered:
a. "Was specimen fixed in 10% neutral buffered formalin within 1 hour from surgical collection time? Yes, No, or Unknown."
b. "Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours? Yes, No, or Unknown."
c. "Was tissue decalcified? Yes, No, or Unknown."
d. "Tumor type? Primary breast carcinoma, metastatic breast carcinoma, or non-breast tumor."
e. "Tumor classification? Invasive breast carcinoma, ductal carcinoma in situ, metastatic breast carcinoma, micro-invasive breast carcinoma, solid/intracystic papillary carcinoma, or non-breast tumor."
Specimen Required
Supplies: Pathology Packaging Kit (T554)
Specimen Type: Breast carcinoma
Preferred: A paraffin-embedded tissue block containing in-situ, invasive or metastatic breast carcinoma tissue that has been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours and shipped at ambient temperature
Acceptable: 3 unstained sections, containing carcinoma, on charged slides cut at 4 microns <1 month ago and shipped at ambient temperature
Collection Instructions: Submit paraffin-embedded carcinoma tissue
Specimen Type: Non-breast carcinoma
Preferred: A paraffin-embedded tissue block containing carcinoma tissue that has been fixed in 10% neutral buffered formalin and shipped at ambient temperature
Acceptable: 3 unstained sections, containing carcinoma, on charged slides cut at 4 microns <1 month ago and shipped at ambient temperature
Collection Instructions: Submit paraffin-embedded carcinoma tissue
Additional Information:
1. According to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, estrogen/progesterone receptor protein immunohistochemical test results are only valid for nondecalcified, paraffin-embedded specimens fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total time of 6 to 72 hours. Delay to fixation, under- or overfixation may affect these results.
2. Paraffin blocks will be returned with final report.
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Special | Ambient (preferred) | ||
| Refrigerated | |||
Reject Due To
No specimen should be rejected.Reference Values
Negative: <1% reactive cells
Positive: ≥1% reactive cells
Day(s) Performed
Monday through Friday
CPT Code Information
88360 x 2
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| ERPR | ER/PR Semi Quant IHC Manual | 10480-2 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 70965 | Interpretation | 50595-8 |
| 70966 | Participated in the Interpretation | No LOINC Needed |
| 70967 | Report electronically signed by | 19139-5 |
| 70969 | Material Received | 81178-6 |
| MA002 | Fixed in 10% NB formalin w/in 1 hr | 8100-0 |
| MA003 | Fixed in 10% NB formalin 6-72 hrs | 8100-0 |
| MA004 | Tumor type | 44638-5 |
| MA005 | Tumor classification | 21918-8 |
| MA044 | Tissue was decalcified | 8100-0 |
| 71620 | Disclaimer | 62364-5 |
| 71834 | Case Number | 80398-1 |
Forms
If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:
-Oncology Test Request (T729)
-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)
Secondary ID
70589Disease States
- Breast cancer
Clinical Information
The steroid hormone receptors, estrogen receptor (ER) and progesterone receptor (PR), are commonly used in the management of women with breast cancer. ER and PR status provide an indication of prognosis and of the potential benefit from hormonal therapy. Generally, ER/PR-positive tumors are more likely to respond to endocrine therapy and have a better prognosis, stage-for-stage, than receptor-negative tumors.
While the test can be performed on any formalin-fixed, paraffin-embedded tissue, it is infrequently used for non-breast cancer specimens.
Interpretation
Immunoperoxidase-stained slides are examined microscopically by the consulting anatomic pathologist and interpreted as negative (<1% reactive cells), or positive. The percent of reactive cells is provided in the report.
Cautions
The performance and quality of immunohistochemical (IHC) stains for formalin-fixed, paraffin-embedded tissue depends critically on proper fixation of tissue specimens. IHC staining of steroid hormone receptors is especially sensitive to fixation conditions (see Specimen Required for specific handling instructions).
Clinical Reference
1. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101
2. Allison KH, Hammond MEH, Dowsett M, et al: Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309
Method Description
Immunoperoxidase staining and detection of estrogen receptor (ER) and progesterone receptor (PR) are performed in formalin-fixed, paraffin-embedded tissue sections using a proprietary kit detection system. The 4-micron tissue sections are deparaffinized, subjected to heat-induced antigen retrieval, and then sequentially incubated with antireceptor monoclonal antibodies (ER clone SP1 and PR clone 1E2) and followed by a proprietary kit detection system. The chromogen, diaminobenzidine, is subsequently applied to the section to produce a brown nuclear precipitate in cells expressing receptors. Sections are lightly counterstained with hematoxylin. Stained slides are examined microscopically by the consulting anatomic pathologist and interpreted as negative (<1% reactive cells), or positive with one of the following ranges: (1%-10% reactive cells), (11%-20% reactive cells), (21%-30% reactive cells), (31%-40% reactive cells), (41%-50% reactive cells), (51%-60% reactive cells), (61%-70% reactive cells), (71%-80% reactive cells), (81%-90% reactive cells), or (91%-100% reactive cells).(Unpublished Mayo method)